Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07219277 · ClinicalTrials.gov registry record
Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening
A clinical trial of Breast Cancer, Liquid Biopsy, Early Detection, sponsored by Syantra.
- Recruiting
- Registry status
- 2,000
- Enrollment target
- 4
- Study locations
NCT07219277: Recruiting study of Breast Cancer, Liquid Biopsy, Early Detection, sponsored by Syantra.
NCT07219277 is a study of Breast Cancer, Liquid Biopsy, Early Detection that is actively recruiting participants, run by Syantra. The registered enrollment target is 2,000 participants. The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07219277, a study of Breast Cancer, Liquid Biopsy, Early Detection, is actively recruiting participants, sponsored by Syantra.
- RECRUITING
- Registry status
- 2,000 participants
- Enrollment target
- 4
- Study locations
Study Summary
Breast cancer is the most common cancer that spreads beyond the initial layer of tissue it developed in, and grows into surrounding healthy tissue in women worldwide. It is associated with significant illness and death. Identifying the disease in the early stage is important to achieving positive outcomes in response to diagnosis and treatment. The Syantra blood test has been developed over the past 10 years. This test involves examining blood samples to identify and analyze specific information. This information is run through a software program that then potentially identifies the presence of breast cancer in the blood sample. This test has the potential to increase early stage detection of breast cancer. The main goal of this study is to figure out how well the Syantra blood test identifies the presence of breast cancer in women 30-75 years of age. The study will also look at whether things like ethnicity, geography and certain individual characteristics (including breast density and elevated risk of breast cancer development) have an effect on how well the test works. This study will recruit women who are attending a visit at the site who are aged 30-75 who are undergoing testing for the presence of breast cancer as part of their regular screening or planned follow up imaging and/or biopsy. Participants who provide consent and meet eligibility criteria will complete a baseline questionnaire and have their blood drawn before any scheduled procedures. Relevant information will be collected from their medical record at the time of joining the study and will be reviewed and updated within 60 days and then again at 12 months following the baseline blood draw. Participants will not have to do anything after the initial visit where they may sign consent, complete the intake questionnaire and have their blood drawn.
Primary Outcome
Sensitivity (Se) if the test = TP/TP+FN), ratio of true positives to true positives and false negatives
Conditions Studied
Study Locations (4)
Arizona
- Vincere Cancer Center - Phoenix
New York
- Weill Cornell Medicine of Cornell University - New York
Alberta
- Alberta Cancer Research Biobank - Calgary
Other
- Manchester University NHS Foundation Trust - Manchester
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 2,000 participants |
| Start Date | 2026-01-07 |
| Est. Completion | 2027-06-14 |
What NCT07219277 shows while recruiting
NCT07219277 is an observational study that tracks outcomes without assigning an intervention. Its 2,000 participants enrollment target places it among the larger protocols in the corpus.
The record links to 1 condition, with Breast Cancer, Liquid Biopsy, Early Detection appearing as the primary indexed condition, and to 0 interventions.
NCT07219277 reports a single indexed study location in Arizona, New York, Alberta.
Frequently Asked Questions
What is clinical trial NCT07219277 about?
NCT07219277 is a clinical study titled "Clinical Validation of Early Detection Blood Test for Universal Large-scale Breast Cancer Screening". Breast cancer is the most common cancer that spreads beyond the initial layer of tissue it developed in, and grows into surrounding healthy tissue in women worldwide. It is associated with significant illness and death. Identifying the disease in the early stage is important to achieving positive ou...
What is the current status of trial NCT07219277?
This trial is currently recruiting. The enrollment target is 2,000 participants. The study started on 2026-01-07. Estimated completion is 2027-06-14.
What conditions does trial NCT07219277 study?
This clinical trial studies the following conditions: Breast Cancer, Liquid Biopsy, Early Detection.
Who is sponsoring clinical trial NCT07219277?
This trial is sponsored by Syantra, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07219277 being conducted?
This trial has 4 study locations across Arizona, New York, Alberta. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00001465 · 2,000 participants
Study of the Disease Process of Lymphangioleiomyomatosis
- NCT00001595 · 2,000 participants
An Investigation of Pituitary Tumors and Related Hypothalmic Disorders
- NCT00138931 · 2,000 participants
Genetics of Cardiovascular and Neuromuscular Disease
- NCT00288119 · 2,000 participants
Genetic Determinants of Barrett's Esophagus and Esophageal Adenocarcinoma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI